08:46 AM EST, 11/20/2025 (MT Newswires) -- BriaCell (BCT.TO) up 6.2% in pre-market trade, said Thursday that it has initiated a research collaboration with Receptor.AI, to expand its small-molecule cancer therapeutics pipeline.

The initiative aims to accelerate the development of selective kinase inhibitors that may improve immune-mediated tumor targeting and cancer patient outcomes.

"This partnership marks an important step in BriaCell's strategic expansion beyond cell-based immunotherapy into small-molecule discovery, reinforcing its mission to deliver differentiated and complementary approaches to cancer treatment," said Dr. William Williams, chief executive.

BriaCell shares are up $0.44, to $7.50, in New York trading.